Evidence map›Paper›PMID 33922033›Full record

ReviewInternational journal of molecular sciences2021

Biomarkers in Prostate Cancer Diagnosis: From Current Knowledge to the Role of Metabolomics and Exosomes.

Stefano Salciccia, Anna Laura Capriotti, Aldo Laganà, Stefano Fais, Mariantonia Logozzi, Ettore De Berardinis, Gian Maria Busetto, Giovanni Battista Di Pierro, Gian Piero Ricciuti, Francesco Del Giudice and 5 more

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
65citing papers in PubMed, 2 pooled it
6.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

65 citing papers in PubMed, 2 syntheses or guidelines pooled it, 102 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Prostate cancer theragnostics biomarkers: An update.Investigative and clinical urology · 2024
    Review
  19. Article
  20. Review

5 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 2 countries.

Stefano SalcicciaDepartment of Urology, Sapienza Rome University, Policlinico Umberto I, 00161 Rome, Italy.
Anna Laura CapriottiDepartment of Chemistry, Sapienza Rome University, 00161 Rome, Italy.
Aldo LaganàDepartment of Chemistry, Sapienza Rome University, 00161 Rome, Italy.ORCID 0000-0003-4963-3020
Stefano FaisDepartment of Oncology and Molecular Medicine, Istituto Superiore di Sanità, 00161 Rome, Italy.
Mariantonia LogozziDepartment of Oncology and Molecular Medicine, Istituto Superiore di Sanità, 00161 Rome, Italy.
Ettore De BerardinisDepartment of Urology, Sapienza Rome University, Policlinico Umberto I, 00161 Rome, Italy.
Gian Maria BusettoDepartment of Urology and Renal Transplantation, University of Foggia, Policlinico Riuniti, 71122 Foggia, Italy.ORCID 0000-0002-7291-0316
Giovanni Battista Di PierroDepartment of Urology, Sapienza Rome University, Policlinico Umberto I, 00161 Rome, Italy.
Gian Piero RicciutiDepartment of Urology, Sapienza Rome University, Policlinico Umberto I, 00161 Rome, Italy.
Francesco Del GiudiceDepartment of Urology, Sapienza Rome University, Policlinico Umberto I, 00161 Rome, Italy.ORCID 0000-0003-3865-5988
Alessandro SciarraDepartment of Urology, Sapienza Rome University, Policlinico Umberto I, 00161 Rome, Italy.
Peter R CarrollDepartment of Urology, UCSF Helen Diller Comprehensive Cancer Center, University of California, San Francisco, CA 94143, USA.
Matthew R CooperbergDepartment of Urology, UCSF Helen Diller Comprehensive Cancer Center, University of California, San Francisco, CA 94143, USA.
Beatrice SciarraDepartment of Chemistry, Sapienza Rome University, 00161 Rome, Italy.
Martina MaggiDepartment of Urology, Sapienza Rome University, Policlinico Umberto I, 00161 Rome, Italy.ORCID 0000-0003-4672-850X
Policlinico Umberto I · ITSapienza University of Rome · ITIstituto Superiore di Sanità · ITUniversity of California, San Francisco · USUniversity of Foggia · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Early detection of prostate cancer (PC) is largely carried out using assessment of prostate-specific antigen (PSA) level; yet it cannot reliably discriminate between benign pathologies and clinically significant forms of PC. To overcome the current limitations of PSA, new urinary and serum biomarkers have been developed in recent years. Although several biomarkers have been explored in various scenarios and patient settings, to date, specific guidelines with a high level of evidence on the use of these markers are lacking. Recent advances in metabolomic, genomics, and proteomics have made new potential biomarkers available. A number of studies focused on the characterization of the specific PC metabolic phenotype using different experimental approaches has been recently reported; yet, to date, research on metabolomic application for PC has focused on a small group of metabolites that have been known to be related to the prostate gland. Exosomes are extracellular vesicles that are secreted from all mammalian cells and virtually detected in all bio-fluids, thus allowing their use as tumor biomarkers. Thanks to a general improvement of the technical equipment to analyze exosomes, we are able to obtain reliable quantitative and qualitative information useful for clinical application. Although some pilot clinical investigations have proposed potential PC biomarkers, data are still preliminary and non-conclusive.

Indexed as

MetabolomeAnimalsBiomarkers, TumorExosomesHumansMaleProstatic NeoplasmsBiomarkers, Tumorbiomarkersearly diagnosisexosomesmetabolomicsprostate cancer

Identifiers

PMID33922033
PMCPMC8122596
OpenAlexW3153135543

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.